Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||CPI-203 + Rucaparib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|CPI-203||BRD4 Inhibitor 7||CPI-203 is an inhibitor of BRD4, which may result in downregulation of Myc and inhibit cell proliferation (PMID: 25299775, PMID: 30991051).|
|Rucaparib||Rubraca||AG014699|PF-01367338|CO-388|AG14447||PARP Inhibitor (Pan) 22||Rubraca (rucaparib) binds to and inhibits PARP, which may result in accumulation of DNA damage and chemosensitization of tumor cells (PMID: 17363489). Rubraca (rucaparib) is FDA approved for use as a maintenance therapy in patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, for treatment in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer harboring deleterious somatic and/or germline BRCA mutations who received 2 or more chemotherapies, and in patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer who received anti-androgen therapy and a taxane-based therapy (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||ovarian cancer||not applicable||CPI-203 + Rucaparib||Preclinical - Cell culture||Actionable||In a preclinical study, the combination of CPI-203 and Rubraca (rucaparib) resulted in a synergistic effect, demonstrating greater growth inhibition of ovarian cancer cells in culture compared to CPI-203 treatment alone (PMID: 32927276).||32927276|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|